8-K: Cue Biopharma Prices $10M Public Offering of Stock and Warrants

Cue Biopharma announced the pricing of an underwritten public offering of common stock and warrants, expected to raise approximately $8.9 million in net proceeds, extending its cash runway into Q1 2027.

Summary

• The company priced an underwritten public offering of 35,714,286 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares of common stock.
• Each share of common stock (or pre-funded warrant) and accompanying common stock warrant are being sold together at a combined public offering price of $0.28 (or $0.279 for pre-funded warrants).
• Each common stock warrant has an exercise price of $0.30 per share, is exercisable immediately, and will expire five years from the date of issuance. Pre-funded warrants have an exercise price of $0.001 per share and are exercisable via cashless exercise.
• The estimated net proceeds from the offering are approximately $8.9 million, or $10.3 million if the underwriters exercise their option to purchase additional securities in full, excluding any proceeds from warrant exercises.
• The company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 5,357,140 shares of common stock and/or warrants to purchase up to 2,678,570 shares of common stock.
• The closing of the offering is expected to take place on or about December 22, 2025.
• The net proceeds, combined with existing cash and $10 million in payments from its collaboration and license agreements with ImmunoScape Pte. Ltd., are expected to fund operations into the first quarter of 2027.

Sentiment

Score: 4

Explanation: While the capital raise addresses a critical 'going concern' issue and extends the cash runway, the significant dilution at a low offering price and the ongoing need for substantial future financing for a clinical-stage company temper the positive impact. The company's reliance on future clinical success and ability to secure further funding remains a key concern.

Positives

• Secured approximately $8.9 million in net proceeds (potentially $10.3 million) from the public offering, providing crucial additional capital.
• The capital raise, combined with existing cash and collaboration payments, is expected to fund operations into the first quarter of 2027, which addresses a previous 'going concern' determination.
• The offering includes pre-funded warrants, which can be attractive to certain institutional investors seeking to limit immediate ownership percentages while still participating in future upside.

Negatives

• The offering price of $0.28 per combined unit (common stock and warrant) is relatively low, indicating significant dilution for existing shareholders.
• The issuance of a large number of warrants (17,857,143 firm warrants, plus up to 2,678,570 option warrants) represents potential future dilution upon exercise.
• The company previously received a Nasdaq deficiency letter on May 12, 2025, indicating compliance issues, though it believes it is in material compliance with listing requirements.

Risks

• Limited operating history, limited cash, and a history of losses.
• Ability to achieve profitability.
• Ability to obtain adequate financing to fund business operations in the future.
• Successfully remediating the current 'going concern' determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months.
• Reliance on licensors, collaborators, contract research organizations, suppliers, and other business partners.
• Potential setbacks in research and development efforts, including negative or inconclusive results from preclinical studies or clinical trials.
• Ability to replicate positive results from preclinical and early-stage clinical trials in later clinical trials.
• Risks associated with the satisfaction of customary closing conditions related to the offering.

Future Outlook

The company estimates that the net proceeds from this offering, combined with existing cash, cash equivalents, marketable securities, and $10 million in payments from its ImmunoScape collaboration, will enable it to fund operations into the first quarter of 2027.

Management Comments

• Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body.
• The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune modulation.
• Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.

Industry Context

This capital raise is typical for clinical-stage biopharmaceutical companies like Cue Biopharma, which require substantial funding for ongoing research and development, particularly for advancing novel therapeutic biologics through preclinical and clinical trials. The offering helps secure the necessary capital to progress its Immuno-STAT platform and product candidates, a common challenge in the high-cost, high-risk biotech sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution from the issuance of new shares and warrants at a low price. However, the capital raise provides necessary funding to continue operations, potentially preserving long-term value if clinical programs succeed.
• Employees: Continued employment and progress on R&D programs are supported by the extended cash runway.
• Creditors: The improved cash position and extended runway reduce immediate solvency risks.
• Customers/Partners: Continued R&D efforts may lead to future products or strengthen existing collaborations.

Next Steps

• Closing of the public offering on or about December 22, 2025.
• Potential exercise of the underwriters' option to purchase additional shares and/or warrants within 30 days.
• Continued efforts to advance its Immuno-STAT platform and product candidates.
• Filing of a final prospectus supplement with the SEC.

Key Dates

Recommendation

The public offering, while highly dilutive at a low price, is a necessary step to address the company's 'going concern' status and extend its cash runway into Q1 2027. This provides a lifeline for Cue Biopharma to continue its clinical-stage development. However, the significant dilution and the inherent risks of a clinical-stage biopharmaceutical company, including the need for substantial future financing and successful clinical trial outcomes, suggest a 'hold' recommendation. Investors should monitor the company's progress in clinical trials and its ability to secure further non-dilutive or less dilutive financing before considering a 'buy' or 'sell' decision.

Keywords

Cue Biopharma, CUE, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, Equity Financing, Biopharmaceutical, Clinical-Stage, Immuno-STAT, Nasdaq Capital Market, H.C. Wainwright & Co., Capital Raise, Dilution, Cash Runway